Liquidia (NASDAQ:LQDA) Bolsa

LIQUIDIA CORP

Liquidia

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Liquidia Corp

Jefferies analyst Sheila Kahyaoglu maintains Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) with a Buy and raises the price target from $230 to $250.

News

Price Target

Analyst Ratings

Jefferies Maintains Buy on Boeing, Raises Price Target to $250

Jefferies analyst Joseph Gallo maintains CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Buy and raises the price target from $410 to $520.

CRWD

Jefferies Maintains Buy on CrowdStrike Holdings, Raises Price Target to $520

Jefferies analyst Brent Thill maintains Asana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NYSE">ASAN</a>) with a Hold and raises the price target from $15 to $17.

ASAN

Jefferies Maintains Hold on Asana, Raises Price Target to $17

<a href="https://www.bloomberg.com/news/articles/2025-06-04/jpmorgan-plans-to-offer-clients-financing-against-crypto-etfs?srnd=homepage-americas">https://www.bloomberg.com/news/articles/2025-06-04/jpmorgan-plans-to-offer-clients-financing-against-crypto-etfs?srnd=homepage-americas</a>

General

'JPMorgan Plans to Offer Clients Financing Against Crypto ETFs'- Bloomberg

CIBC analyst Mark Jarvi maintains Algonquin Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AQN#NYSE">AQN</a>) with a Neutral and raises the price target from $5.75 to $6.25.

CIBC Maintains Neutral on Algonquin Power, Raises Price Target to $6.25

<a href="https://www.ft.com/content/0c76f3c2-7213-42a5-8f30-b101b7616db0">https://www.ft.com/content/0c76f3c2-7213-42a5-8f30-b101b7616db0</a>

AAPL

BABA

'Apple and Alibaba's AI rollout in China delayed by Donald Trump's trade war'- Financial Times

Morgan Stanley analyst Betsy Graseck maintains Wells Fargo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) with a Overweight and raises the price target from $77 to $87.

Morgan Stanley Maintains Overweight on Wells Fargo, Raises Price Target to $87

Trading Ideas

WHLR

Wheeler Real Estate Investment Trust Shares Halted On Circuit Breaker To The Upside, Stock Now Up 81.9%

TOPS

TOP Ships Shares Resume Trade

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates aTyr Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATYR#NASDAQ">ATYR</a>) with a Buy and maintains $35 price target.

Reiteration

ATYR

HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target

Before he became a billionaire, starred on "Shark Tank," sold the NBA's Dallas Mavericks, or trolled Elon Musk on social media, Mark Cuban had a much simpler dream: <a href="https://www.benzinga.com/news/25/05/45600579/mark-cuban-planned-to-quit-working-after-he-made-millions-in-his-30s-im-not-retired-because-im-too">save up enough to retire</a> by 35—not because he wanted to coast, but because he wanted to live.
In a 2020 <a href="https://youtu.be/DO6agHwHmFo?si=0xvvDia3o8ZVCuuR">episode of the "Venture Voice" podcast</a>, Cuban laid it all out. His goal was never about sipping piña coladas at 11 a.m. It was about never having to ask permission again.
"I just wanna be able to do whatever I want, whenever I want, however I wanted to do it," he said. "And I got really good at it."
Don't Miss:
<ul class="wp-block-list">
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.</li>
<li><a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a></li>
</ul>
That mindset didn't come out of thin air. It started with a beat-up Fiat, discount groceries, and <a href="https://www.benzinga.com/personal-finance/24/11/41973781/mark-cuban-drove-an-abandoned-car-he-found-after-his-200-fiat-with-holes-in-the-floorboard-died-i-was-determined-to-be-able-to-retire">a $200 budget for cars</a>.
"Live like a student," Cuban said, channeling his inner FIRE bro — one of those financial independence, retire early types — before it even had a name. The formula? Stash cash, live cheap, and let interest rates do the heavy lifting.
"If I could save $100,000 and live off of, you know, 5… whatever it was. Right? 10,000 a 100,000, 10% interest rate," he continued. "So $100,000 went $10,000 a year. If I could get up to $250,000 then I'd have $25,000. Could I live off of that? Yeah. Back then, I thought I could live off of it and that was my orientation, save up enough so I could retire and live like a student."
Trending: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
The big "why" behind that scrappy plan? Watching his dad grind away, six days a week, with hardly a minute to himself.
"My dad really didn't have his own time to himself," Cuban recalled. "Every morning, you know, he was at work or leaving for work at 7 a.m., six days a week. You know, he got home at, you know, noon or 1 on Saturdays, and that was half a day off."
His father's go-to line—equal parts reminder and rally cry—stuck: "Today's the youngest you'll ever be. Live like it."
See Also: Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.
So while most people saw retirement as an escape hatch, Cuban saw it as a power move. Not to stop working, but to own his time.
That's what $1 million meant to him back then. Not yacht money. Not jet money. Just enough to live, roam, and "<a href="https://www.benzinga.com/25/05/45553078/mark-cuban-says-you-dont-need-to-have-life-figured-out-by-22-he-got-fired-slept-on-the-floor-partied-like-a-rockstar-and-still-became-rich">party like a rock star" but still live like a student</a>, as he once put it.
And now? He's still working. Still building. Still doing exactly what he wants.
Because for Cuban, that was always the point.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
</ul>
Image: Shutterstock

Personal Finance

Mark Cuban Wanted To Get Rich Enough To Retire By 35—Not To Quit Working, But For Freedom: 'Today Is the Youngest You'll Ever Be. Live Like It'

GFL Environmental (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFL#NYSE">GFL</a>) has outperformed the market over the past 5 years by 7.3% on an annualized basis producing an average annual return of 20.53%. Currently, GFL Environmental has a market capitalization of $18.12 billion. 
Buying $100 In GFL: If an investor had bought $100 of GFL stock 5 years ago, it would be worth $245.50 today based on a price of $49.42 for GFL at the time of writing.
<h3>GFL Environmental's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749051918_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In GFL Environmental 5 Years Ago Would Be Worth Today

<a href="https://www.aboutamazon.com/news/aws/aws-investment-north-carolina-ai-cloud-infrastructure">https://www.aboutamazon.com/news/aws/aws-investment-north-carolina-ai-cloud-infrastructure</a>

AMZN

'Amazon Plans To Invest $10 Billion In North Carolina To Expand Cloud Computing Infrastructure And Advance AI Innovation'

Morgan Stanley analyst Meta Marshall maintains Lumentum Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) with a Equal-Weight and raises the price target from $70 to $76.

LITE

Morgan Stanley Maintains Equal-Weight on Lumentum Holdings, Raises Price Target to $76

Tigress Financial analyst Ivan Feinseth initiates coverage on Intl Flavors &amp; Fragrances (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFF#NYSE">IFF</a>) with a Buy rating and announces Price Target of $105.

Initiation

Tigress Financial Initiates Coverage On Intl Flavors & Fragrances with Buy Rating, Announces Price Target of $105

TOP Ships Shares Halted On Circuit Breaker To The Upside, Stock Now Up 46.9%

Shares of Asana Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NYSE">ASAN</a>) tanked 17.71% at last check on Wednesday, despite the company&#8217;s recent <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45758525/asana-stock-climbs-on-mixed-q1-earnings-earnings-beat-revenues-miss">earnings beat</a>.
Here are some key analyst takeaways.
<ul class="wp-block-list">
<li>Piper Sandler <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/586e4055351b9b00018beeab/brent-bracelin">analyst Brent Bracelin</a> maintained an Overweight rating, while raising the price target from $17 to $19.</li>
<li>RBC Capital Markets <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5846fffaee7bf6000154d142/rishi-jaluria">analyst Rishi Jaluria</a> reiterated an Underperform rating and price target of $10.</li>
<li>JMP Securities <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5846fffaee7bf6000154d141/patrick-walravens">analyst Patrick Walravens</a> reaffirmed a Market Outperform rating and price target of $22.</li>
<li>KeyBanc <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58777fa15064ed000173004c/jackson-ader">analyst Jackson Ader</a> maintained a Sector Weight rating on the stock.</li>
</ul>
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Piper Sandler: Asana delivered a revenue beat of 1.0% to the midpoint of its guidance, resulting in 8.6% growth. Total revenue amounted to $187 million. Bracelin noted that $100,000+ ARR (annual recurring revenue) customers totaled 728, up 20% year-on-year.
Operating margin came in at 4.3%, much higher than the guidance midpoint of 1.3%, while management projected 4.7% at the midpoint for the second quarter. They raised the full-year operating margin guidance to 5.5%, from their prior outlook of 5.0%, implying "a favorable margin progression through the rest of F2026, reinforcing our confidence in the continued focus on driving operating leverage," Bracelin wrote.
RBC Capital Markets: Asana reported revenue of $187.3 million, up 9% year-on-year, beating consensus of $185.4 million, Jaluria said. Non-GAAP earnings of 5 cents per share also came in ahead of consensus of 2 cents per share, he added.
Billings, RPO, and cRPO (current remaining performance obligation) were impacted by deal renewal shifting to the second quarter, the analyst stated. "NRR continues to be impacted by lack of expansion from macro pressures, specifically in the tech vertical, as overall, core customer, and $100K+ customer NRR all declined by 1 point QoQ," he further wrote.
JMP Securities: Asana posted positive operating margin for the first time in its history, Walravens said. Although revenues grew 9% year-on-year, they were down 10% sequentially, he added.
Billings of $175 million came in short of consensus of $213 million. At the same time, RPO growth of 11% missed expectations of 13%. 
Asana's largest deal in history slipped into 2Q. Asana widened its full-year revenue guidance range to $775-$790 million, citing "a growing macroeconomic risk," Walravens further wrote.
KeyBanc Capital: Asana inked its largest deal in history during the first quarter, with a total contract value of $100 million, Ader said. Although this renewal and expansion deal extended the contract term from one year to three years, it represents a lower average annual contract value (ACV), he added.
Management lowered the midpoint of their revenue range by $3.5 million, due to the large customer contract and other macro uncertainty, the analyst stated. "Overall, though, we feel incrementally worse about the trends going forward," he further wrote.
ASAN Price Action: Shares of Asana are currently trading at around $15.64 at the time of publication on Wednesday.
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45262278/under-armour-faces-tough-road-ahead-says-analyst">Asana Growth Materially Lags Peers, JP Morgan Cuts Price Forecast</a></li>
</ul>
Image: Shutterstock

Analyst Color

Earnings Beats

Movers

Asana Posts First Ever Positive Operating Margin, Signs Largest Heal In History

Benchmark analyst David Williams reiterates Plexus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLXS#NASDAQ">PLXS</a>) with a Buy and maintains $160 price target.

PLXS

Benchmark Reiterates Buy on Plexus, Maintains $160 Price Target

DA Davidson analyst Gil Luria maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Buy and maintains $250 price target.

SNOW

DA Davidson Maintains Buy on Snowflake, Maintains $250 Price Target

DA Davidson analyst Peter Heckmann maintains Guidewire Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) with a Neutral and maintains $226 price target.

GWRE

DA Davidson Maintains Neutral on Guidewire Software, Maintains $226 Price Target

Press Releases

Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference

UPDATE – Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference

Earnings

Liquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025

Health Care

Legal

District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia

Liquidia Corporation to Present at BofA Securities 2025 Health Care Conference

Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update

Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics

U.S. FDA Approves Liquidia's YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Comments

Liquidia

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL